Literature DB >> 2481353

Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues.

R Veggian1, S Fasolato, S Ménard, D Minucci, P Pizzetti, M Regazzoni, E Tagliabue, M I Colnaghi.   

Abstract

The reactivity profile of the monoclonal antibody (MAb) MOv18, raised against a poorly differentiated ovarian carcinoma specimen, was studied on normal tissues and tumors from the female reproductive system and on the kidney, which like the oviducts, vagina and uterus, also derives from the intermediate mesoderm. The obtained results indicate that MOv18 recognizes an epitope present on the normal epithelium of the oviducts, on 14-week old fetal kidney and, focally, on proximal and distal tubules of normal adult kidney. A strong reactivity was found on ovarian carcinomas, on invasive squamous carcinomas of the cervix and on endometrial carcinomas and hyperplasias. The antigen recognized by MOv18 (CaMOv18) therefore seems to be an epithelial cell marker associated with intermediate mesoderm differentiation, which can be derepressed during the neoplastic transformation of the ovary and the uterus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481353     DOI: 10.1177/030089168907500524

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  8 in total

Review 1.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.

Authors:  P Garin-Chesa; I Campbell; P E Saigo; J L Lewis; L J Old; W J Rettig
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

3.  Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences.

Authors:  C Alexander; C E Villena-Heinsen; L Trampert; S Lung-Kurt; E Oberhausen; C M Kirsch; W Schmidt
Journal:  Eur J Nucl Med       Date:  1995-07

4.  Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts.

Authors:  S D Konda; M Aref; S Wang; M Brechbiel; E C Wiener
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

5.  Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

Authors:  M Köbel; J Madore; S J Ramus; B A Clarke; P D P Pharoah; S Deen; D D Bowtell; K Odunsi; U Menon; C Morrison; S Lele; W Bshara; L Sucheston; M W Beckmann; A Hein; F C Thiel; A Hartmann; D L Wachter; M S Anglesio; E Høgdall; A Jensen; C Høgdall; K R Kalli; B L Fridley; G L Keeney; Z C Fogarty; R A Vierkant; S Liu; S Cho; G Nelson; P Ghatage; A Gentry-Maharaj; S A Gayther; E Benjamin; M Widschwendter; M P Intermaggio; B Rosen; M Q Bernardini; H Mackay; A Oza; P Shaw; M Jimenez-Linan; K E Driver; J Alsop; M Mack; J M Koziak; H Steed; C Ewanowich; A DeFazio; G Chenevix-Trench; S Fereday; B Gao; S E Johnatty; J George; L Galletta; E L Goode; S K Kjær; D G Huntsman; P A Fasching; K B Moysich; J D Brenton; L E Kelemen
Journal:  Br J Cancer       Date:  2014-10-30       Impact factor: 7.640

6.  Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.

Authors:  Daniel J O'Shannessy; Elizabeth B Somers; Leslie M Palmer; Robert P Thiel; Pankaj Oberoi; Ryan Heath; Lisa Marcucci
Journal:  J Ovarian Res       Date:  2013-04-17       Impact factor: 4.234

Review 7.  The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.

Authors:  Sita Kugel Desmoulin; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

8.  Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas.

Authors:  A Viel; L Dall'Agnese; F Simone; V Canzonieri; E Capozzi; M C Visentin; R Valle; M Boiocchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.